Wrong About Inflammation & Heart Disease

The Inflammaging Hypothesis00:00:00

Interleukin-6 (IL-6) was long considered a master aging switch and a key driver of heart disease. Researchers observed that high levels of IL-6 were linked to faster aging and mortality, leading to the hypothesis that lowering it could provide a medical breakthrough.

Genetic and Clinical Evidence00:01:37

Mendelian randomization studies suggested that individuals with genetically lower IL-6 levels had better cardiovascular outcomes. This encouraged the development of drugs to target inflammation, leading to positive results in the CANTOS trial, though it highlighted an increased risk of infection.

The Failure of Targeted Blocking00:05:12

Despite promising early data, the recent ZEUS trial, which directly blocked IL-6, failed to reduce cardiovascular events. This suggests that simply 'shooting the messenger' (the inflammatory markers) is ineffective and potentially harmful, as these markers are necessary for immune function and exercise-induced fat loss.

Targeting the Root Cause00:07:34

The inflammation hypothesis is not dead, but the approach must shift to addressing the root causes of chronic inflammation, such as visceral fat. Interventions like weight loss via lifestyle changes or GLP-1 agonists effectively lower inflammation as a byproduct of improving metabolic health.